Avadel Pharmaceuticals Announces Publication of Study Data in Advances in Therapy Highlighting Need for Once-at-Bedtime Oxybate Dosing for Narcolepsy
June 13, 2023 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, June 13, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the publication of...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, June 06, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Pharmaceuticals Announces U.S. Commercial Launch of LUMRYZ™ (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Adults Living with Narcolepsy
June 05, 2023 07:00 ET
|
Avadel Pharmaceuticals plc
-LUMRYZ is the first and only once-at-bedtime oxybate for people living with narcolepsy -Once-nightly dosing regimen of LUMRYZ has been found by FDA to provide a major contribution to patient care...
Avadel Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 01, 2023 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, June 01, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023
May 31, 2023 16:00 ET
|
Avadel Pharmaceuticals plc
– 12 accepted abstracts highlight Company’s emerging leadership in narcolepsy – – Data adds to growing body of evidence demonstrating positive clinical benefit and patient preference of...
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 04, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
-- Received FDA approval for LUMRYZ™ (sodium oxybate), the first and only once-at-bedtime oxybate for treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy – -- FDA...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, May 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of...
Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy
May 01, 2023 13:20 ET
|
Avadel Pharmaceuticals plc
- Granted Orphan Drug Exclusivity through May 1, 2030 - -Advanced commercial preparations on track; LUMRYZ product availability expected in early June - - Final approval supported by robust efficacy...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
April 20, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, April 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare Conference
April 10, 2023 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, April 10, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...